FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293236003> ?p ?o ?g. }

• W4293236003 endingPage "61" @default.
• W4293236003 startingPage "49" @default.
• W4293236003 abstract "Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by progressive degeneration of both upper and lower motor neurons, resulting in paralysis and eventually leads to death from respiratory failure typically within 3 to 5 years of symptom onset. The aim of this work was to predict the pharmacokinetics and identify unique protein targets that are associated with potential anti-ALS phytochemicals and FDA-approved drugs, by in silico approaches.&#x0D; Materials and methods: Standard computational tools (webserver and software) were used, and the methods used are clustering analysis, pharmacokinetics and molecular target predictions, and molecular docking simulation.&#x0D; Results and discussion: The results show that riluzole, β-asarone, cryptotanshinone, harmine and 7,8-dihydroxyflavone have similar pharmacokinetics properties. Riluzole and harmine show 95% probability of target on norepinephrine transporter. Huperzine-A and cryptotanshinone show 100% probability of target on acetylcholinesterase. 7,8-dihydroxyflavone shows 35% probability of target on several carbonic anhydrases, 40% probability of target on CYP19A1, and 100% probability of target on inhibitor of nuclear factor kappa B kinase beta subunit and neurotrophic tyrosine kinase receptor type 2, respectively. Harmine also shows 95% probability of target on dual specificity tyrosine-phosphorylation-regulated kinases, threonine-protein kinases (haspin and PIM3), adrenergic receptors, cyclin-dependent kinases (CDK5 and CDK9), monoamine oxidase A, casein kinase I delta, serotonin receptors, dual specificity protein kinases (CLK1, CLK2, and CLK4), and nischarin, respectively. Also, the results of gene expression network show possible involvement of CDK1, CDK2, CDK4, ERK1, ERK2 and MAPK14 signaling pathways. This study shows that riluzole and harmine have closely similar physicochemical and pharmacokinetics properties as well as molecular targets, such as norepinephrine transporter (SLC6A2). Harmine, huperzine-A and cryptotanshinone could modulate acetylcholinesterase (AChE), which is involved in ALS-pathogenesis. The impact of 7,8-dihydroxyflavone on several carbonic anhydrases (CA) I, II, VII, IX, XII, and XIV, as well as CYP19A1, could help in remediating the respiratory failure associated with ALS.&#x0D; Conclusion: Overall, harmine is found to be superior to riluzole, and the combination of harmine with 7,8-dihydroxyflavone can provide more effective treatment for ALS than the current regime. Further work is needed to validate the predicted therapeutic targets of harmine identified in this study on ALS model or clinical trials, using in silico, in vitro and in vivo techniques.&#x0D; Graphical abstract:" @default.
• W4293236003 created "2022-08-27" @default.
• W4293236003 creator A5008323116 @default.
• W4293236003 creator A5017445228 @default.
• W4293236003 creator A5020110362 @default.
• W4293236003 creator A5038507698 @default.
• W4293236003 creator A5042389200 @default.
• W4293236003 creator A5048999967 @default.
• W4293236003 creator A5071898626 @default.
• W4293236003 creator A5075588767 @default.
• W4293236003 creator A5078242867 @default.
• W4293236003 creator A5085355565 @default.
• W4293236003 creator A5089765021 @default.
• W4293236003 date "2022-08-25" @default.
• W4293236003 modified "2023-10-01" @default.
• W4293236003 title "Harmine and 7,8-dihydroxyflavone synergistically suitable for amyotrophic lateral sclerosis management: An in silico study" @default.
• W4293236003 cites W1482520638 @default.
• W4293236003 cites W1520966255 @default.
• W4293236003 cites W17281879 @default.
• W4293236003 cites W1945385027 @default.
• W4293236003 cites W1971689949 @default.
• W4293236003 cites W1979637658 @default.
• W4293236003 cites W2004370047 @default.
• W4293236003 cites W2028382512 @default.
• W4293236003 cites W2031099654 @default.
• W4293236003 cites W2032704903 @default.
• W4293236003 cites W2045996940 @default.
• W4293236003 cites W2053031271 @default.
• W4293236003 cites W2067015275 @default.
• W4293236003 cites W2095997832 @default.
• W4293236003 cites W2101808966 @default.
• W4293236003 cites W2105668062 @default.
• W4293236003 cites W2112332844 @default.
• W4293236003 cites W2129438079 @default.
• W4293236003 cites W2134967712 @default.
• W4293236003 cites W2149472336 @default.
• W4293236003 cites W2153451653 @default.
• W4293236003 cites W2160683179 @default.
• W4293236003 cites W2163119148 @default.
• W4293236003 cites W2163275503 @default.
• W4293236003 cites W2168175722 @default.
• W4293236003 cites W2192524675 @default.
• W4293236003 cites W2232649956 @default.
• W4293236003 cites W2236767140 @default.
• W4293236003 cites W2308457054 @default.
• W4293236003 cites W2511577826 @default.
• W4293236003 cites W2562417922 @default.
• W4293236003 cites W2578119541 @default.
• W4293236003 cites W2592775972 @default.
• W4293236003 cites W2593436234 @default.
• W4293236003 cites W2611815300 @default.
• W4293236003 cites W2743843493 @default.
• W4293236003 cites W2750714493 @default.
• W4293236003 cites W2789726442 @default.
• W4293236003 cites W2797335506 @default.
• W4293236003 cites W2804408552 @default.
• W4293236003 cites W2907546400 @default.
• W4293236003 cites W2909299904 @default.
• W4293236003 cites W2946412700 @default.
• W4293236003 cites W2949575704 @default.
• W4293236003 cites W2980871495 @default.
• W4293236003 cites W3025051439 @default.
• W4293236003 cites W3108335720 @default.
• W4293236003 cites W3124211297 @default.
• W4293236003 cites W3124559005 @default.
• W4293236003 cites W4236210456 @default.
• W4293236003 cites W4252979096 @default.
• W4293236003 doi "https://doi.org/10.3897/rrpharmacology.8.83332" @default.
• W4293236003 hasPublicationYear "2022" @default.
• W4293236003 type Work @default.
• W4293236003 citedByCount "5" @default.
• W4293236003 countsByYear W42932360032023 @default.
• W4293236003 crossrefType "journal-article" @default.
• W4293236003 hasAuthorship W4293236003A5008323116 @default.
• W4293236003 hasAuthorship W4293236003A5017445228 @default.
• W4293236003 hasAuthorship W4293236003A5020110362 @default.
• W4293236003 hasAuthorship W4293236003A5038507698 @default.
• W4293236003 hasAuthorship W4293236003A5042389200 @default.
• W4293236003 hasAuthorship W4293236003A5048999967 @default.
• W4293236003 hasAuthorship W4293236003A5071898626 @default.
• W4293236003 hasAuthorship W4293236003A5075588767 @default.
• W4293236003 hasAuthorship W4293236003A5078242867 @default.
• W4293236003 hasAuthorship W4293236003A5085355565 @default.
• W4293236003 hasAuthorship W4293236003A5089765021 @default.
• W4293236003 hasBestOaLocation W42932360031 @default.
• W4293236003 hasConcept C126322002 @default.
• W4293236003 hasConcept C184235292 @default.
• W4293236003 hasConcept C185592680 @default.
• W4293236003 hasConcept C2779134260 @default.
• W4293236003 hasConcept C2780596555 @default.
• W4293236003 hasConcept C2781450507 @default.
• W4293236003 hasConcept C55493867 @default.
• W4293236003 hasConcept C71924100 @default.
• W4293236003 hasConcept C86803240 @default.
• W4293236003 hasConcept C98274493 @default.
• W4293236003 hasConceptScore W4293236003C126322002 @default.
• W4293236003 hasConceptScore W4293236003C184235292 @default.
• W4293236003 hasConceptScore W4293236003C185592680 @default.

• next